ArticleHepatology international2026

TACE and tyrosine kinase inhibitors with or without PD-1 inhibitors as first-line therapy for intermediate-advanced HCC: a multicenter real-world cohort study.

Xue-Gang Yang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.